Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Inthepezon Aug 18, 2021 1:41am
132 Views
Post# 33722043

RE:Sad

RE:SadYou never made point, you gave a FUD opinion. From an account that was made earlier this week.
 
But mr. August 12 account, I’ll address what you wrote just to put you in your place. yes it may drop below a dollar, such is the nature of small cap biotech in Canada. Great academic infrastructure but poor capital markets. Hence why the need to go to the US.

This is a great example of FUD. You think they’re going to cancel this program that had unequivocal proof of concept for GI safety, over ALT elevation? That’s FUD. ALT elevation is a class by product of NSAIDs. 75mg will be powerful because of the thromboxane suppression seen in phase 1. And there is even data to suggest 50mg will work well. 

The delay is real. Your fud isn’t. And that’s what feed off of. And most people see right through you, Yukonjizz face lol

Rarbar99 wrote:

Just notice how 3 people responded to my comment and none of them could refute a single point. They just called me a troll because they know I'm right. 

and just so you know, in 2 months this will likely drop even further. There's a good chance the report will be unfavourable, and there's a strong possibility that they will entirely cancel the project. But we still have to wait 2 months just to hear that. A slow death -- if you will. Good luck.



<< Previous
Bullboard Posts
Next >>